Eli Lilly (LLY) Receivables (2009 - 2026)

Eli Lilly has reported Receivables for 18 years, with the latest figure at $21.2 billion in Q1 2026.

• For the quarter ending Q1 2026, Receivables rose 51.23% year-over-year to $21.2 billion; the trailing twelve-month figure through Mar 2026 stood at $21.2 billion (up 51.23% YoY), and the FY2025 full-year result was $20.2 billion, up 51.82% from the prior year.
• Receivables for Q1 2026 stood at $21.2 billion, up from $20.2 billion in the prior quarter.
• The five-year high for Receivables was $21.2 billion in Q1 2026, with the low at $7.7 billion in Q2 2022.
• Historically, Receivables has averaged $12.5 billion across 5 years, with a median of $11.3 billion in 2023.
• Annual changes were most pronounced in 2022 — Receivables rose 5.31% — and 2025, when it soared 61.45%.
• Eli Lilly's Receivables stood at $8.6 billion in 2022, then surged by 32.45% to $11.3 billion in 2023, then climbed by 17.11% to $13.3 billion in 2024, then soared by 51.82% to $20.2 billion in 2025, then grew by 5.07% to $21.2 billion in 2026.
• The last three Receivables figures came in at $21.2 billion (Q1 2026), $20.2 billion (Q4 2025), and $19.5 billion (Q3 2025), per Business Quant data.